Zongertinib shows promising results in HER2-mutant NSCLC, offering high response rates and improved quality of life with minimal toxicity.
Joshua K. Sabari, MD
Advertisement
Articles by Joshua K. Sabari, MD
Advertisement
Latest Updated Articles
PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low ToxicityPublished: July 1st 2025 | Updated: June 30th 2025
Advertisement
Advertisement
Trending on AJMC
1
Rural-Urban Disparities in Colorectal Cancer Screening Persist
2
Medicaid Work Rules Could Strain Hospitals: Laxmi Patel
3
Insurance Coverage Improves for Same-Sex Couples, Yet Disparities Persist
4
Identifying Barriers to Colorectal Cancer Screening for People With IDD
5
